Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 7 studies | 30% ± 11% | |
enterocyte | 4 studies | 19% ± 2% | |
goblet cell | 4 studies | 22% ± 6% | |
pancreatic A cell | 3 studies | 28% ± 15% | |
enteroendocrine cell | 3 studies | 21% ± 8% | |
basal cell | 3 studies | 29% ± 9% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
intestine | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 3802.80 | 328 / 328 | 100% | 43.73 | 178 / 178 |
lung | 99% | 4140.45 | 575 / 578 | 99% | 66.36 | 1149 / 1155 |
thymus | 100% | 3384.64 | 652 / 653 | 96% | 63.70 | 583 / 605 |
stomach | 89% | 2556.40 | 318 / 359 | 99% | 64.41 | 282 / 286 |
prostate | 95% | 3033.68 | 232 / 245 | 91% | 31.88 | 455 / 502 |
breast | 86% | 2740.43 | 395 / 459 | 99% | 55.43 | 1104 / 1118 |
kidney | 99% | 2547.89 | 88 / 89 | 83% | 23.16 | 745 / 901 |
adrenal gland | 100% | 8475.00 | 258 / 258 | 80% | 50.77 | 185 / 230 |
esophagus | 64% | 4691.50 | 923 / 1445 | 100% | 57.61 | 183 / 183 |
intestine | 64% | 4244.72 | 620 / 966 | 99% | 76.14 | 522 / 527 |
bladder | 62% | 1661.62 | 13 / 21 | 99% | 66.13 | 498 / 504 |
uterus | 59% | 1053.55 | 101 / 170 | 87% | 51.58 | 401 / 459 |
ovary | 53% | 787.54 | 96 / 180 | 87% | 21.45 | 373 / 430 |
skin | 98% | 8391.49 | 1769 / 1809 | 14% | 3.23 | 68 / 472 |
spleen | 100% | 3203.85 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 71.11 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 51.78 | 1 / 1 |
peripheral blood | 87% | 4172.53 | 812 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 66% | 15.49 | 19 / 29 |
adipose | 63% | 1111.76 | 762 / 1204 | 0% | 0 | 0 / 0 |
liver | 17% | 276.75 | 39 / 226 | 30% | 10.43 | 122 / 406 |
brain | 41% | 713.93 | 1093 / 2642 | 5% | 0.72 | 36 / 705 |
blood vessel | 13% | 184.21 | 172 / 1335 | 0% | 0 | 0 / 0 |
heart | 2% | 30.78 | 21 / 861 | 0% | 0 | 0 / 0 |
muscle | 0% | 3.41 | 2 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1903936 | Biological process | cellular response to sodium arsenite |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0034644 | Biological process | cellular response to UV |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_0072709 | Biological process | cellular response to sorbitol |
GO_0006970 | Biological process | response to osmotic stress |
GO_0072740 | Biological process | cellular response to anisomycin |
GO_0051403 | Biological process | stress-activated MAPK cascade |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0070301 | Biological process | cellular response to hydrogen peroxide |
GO_0032755 | Biological process | positive regulation of interleukin-6 production |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004707 | Molecular function | MAP kinase activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MAPK13 |
Protein name | Mitogen-activated protein kinase 13 Mitogen-activated protein kinase 13 (MAP kinase 13) (MAPK 13) (EC 2.7.11.24) (Mitogen-activated protein kinase p38 delta) (MAP kinase p38 delta) (Stress-activated protein kinase 4) Mitogen-activated protein kinase 13 (EC 2.7.11.24) |
Synonyms | PRKM13 SAPK4 |
Description | FUNCTION: Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK13 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors such as ELK1 and ATF2. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. MAPK13 is one of the less studied p38 MAPK isoforms. Some of the targets are downstream kinases such as MAPKAPK2, which are activated through phosphorylation and further phosphorylate additional targets. Plays a role in the regulation of protein translation by phosphorylating and inactivating EEF2K. Involved in cytoskeletal remodeling through phosphorylation of MAPT and STMN1. Mediates UV irradiation induced up-regulation of the gene expression of CXCL14. Plays an important role in the regulation of epidermal keratinocyte differentiation, apoptosis and skin tumor development. Phosphorylates the transcriptional activator MYB in response to stress which leads to rapid MYB degradation via a proteasome-dependent pathway. MAPK13 also phosphorylates and down-regulates PRKD1 during regulation of insulin secretion in pancreatic beta cells. . |
Accessions | O15264 ENST00000373766.9 [O15264-2] Q5R3E6 ENST00000211287.9 [O15264-1] Q6FHR4 ENST00000373759.1 A0A0S2Z542 A0A024RD04 B5BTY5 |